The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis Declared competing interests of authors: none of the authors has any conflicts of interest. Dr P Jobanputra is a member of the British Society for Rheumatology. He was not involved in formulating guidelines for the use of anakinra proposed by the British Society for Rheumatology, nor was he involved in any other submissions to the National Institute for Clinical Excellence.Note: a small amount of information was submitted to the National Institute for Clinical Excellence in confidence and has been removed from this version of the report. However, it should be noted that the Institute's Appraisal Committee had access to the full report to draw up their guidance. Published May 2004This report should be referenced as follows:Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess 2004;8(18). Health Technology Assessment is indexed in Index Medicus/MEDLINE and Excerpta Medica/ EMBASE. NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the...

Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug  Effectiveness Review Project

“…Our results are consistent with several other published systematic reviews of anakinra. 20,[41][42][43] In one RCT that used a combination of anakinra and etanercept the response rates were not better than etanercept alone, and the adverse events rates were significantly higher. There appears to be greater harm and no additional benefit in combining anakinra and the anti-TNF drugs.…”

Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases

“…However, efficacy results were generally inferior to those reported for the TNF inhibitors (not head-to-head studies). Therefore, although anakinra is licensed for use in active RA, it was not cost-effective (Clark et al, 2004) and is generally not recommended in current treatment guidelines because of the lower efficacy compared with other biologics .…”

INTERLEIKIN 1 KAK MEDIATOR VOSPALENIYa I TERAPEVTIChESKAYa MIShEN''

“…Сравнительный анализ эффе-ктивности анакинры и ингибиторов ФНО показал, что анакинра менее эффективна, чем этанерцепт: отношение шансов (ОШ) 0,34; 95% доверительный интервал (ДИ) 0,14-0,81 -и адалимумаб: ОШ 0,45; 95% ДИ 0,21-0,99 [53,54]. Таким образом, анакинра при РА обычно не ис-пользуется в качестве терапии первой линии, но может применяться для лечения группы пациентов, у которых на-блюдается неэффективность ингибиторов ФНО [53][54][55][56][57]. Является ли относительно низкая эффективность анакин-ры в лечении РА следствием того, что ИЛ 1 играет мень-шую роль в патогенезе РА, чем ФНО, либо недостаточный эффект анакинры обусловлен коротким периодом полу-распада (от 4 до 6 ч), не позволяющим нейтрализовать ИЛ 1 в полном объеме, -остается не ясным [58].…”